SPECIAL REPORT

Niacin-laropiprant adjunct to statin therapy poses risks to heart patients, study says

Patients with atherosclerotic vascular disease receiving extended-release niacin and laropiprant along with statin therapy did not benefit in terms of prevention of major vascular events compared with those taking placebo and statins. In addition, individuals who received the niacin-laropiprant adjunct had serious side effects, including diabetes, gastrointestinal disturbances, infections, and bleeding, according to a report in the New England Journal of Medicine.

Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control…and with an increased incidence of diabetes diagnoses.

Other Coverage

• Niacin ER as adjunct to statins does not reduce CV outcomes

• Lower-statin combo therapy good option for some heart patients

• How safe is statin therapy?

Editorial Questions? Contact the Editorial Team. Click Here.
Sales, Reprints, Classified questions? Contact the Sales Team. Click Here.